



## Challenges and Therapeutic Prospects in Hematology Oncology

Guest Editor:

**Dr. Magdalena Witkowska**

Department of Experimental  
Hematology, Medical University  
of Lodz, 93-510 Lodz, Poland

Deadline for manuscript  
submissions:


**5 May 2024**

### Message from the Guest Editor

Hematological diseases, usually persisting in the blood, lymphoma and/or bone marrow, render surgical and local treatments for solid tumors clinically ineffective. The presence and resistance of cancer stem cells (CSC) further make them difficult to cure. The development of new personalized therapies, such as molecularly targeted drugs, monoclonal and bispecific antibodies and CART-T cells, has improved the clinical outcome of lymphoproliferative diseases.

This Special Issue, entitled "Challenges and Therapeutic Prospects in Hematology Oncology", aims to update clinical aspects of hematologic malignancies, such as lymphoma, leukemia and multiple myeloma, with research articles as well as comprehensive review papers addressing the state of the art and the future perspectives of hematologic malignancies, focusing preferentially on innovative research in diagnosis, prognosis and personalized therapy.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Senior Vice President and Director, Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Professor of Medicine Chief, Section of Hematologic Malignancies, Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute, Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:**— free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[@JPM\\_MDPI](https://twitter.com/JPM_MDPI)